Cargando…

Utility of the p53 mutant protein in patients with low-risk myelodysplastic syndrome

Detalles Bibliográficos
Autores principales:	Yao, David C., de Lima, Marcos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Sociedade Brasileira de Hematologia e Hemoterapia 2014
Materias:	Scientific Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109744/ https://www.ncbi.nlm.nih.gov/pubmed/25031053 http://dx.doi.org/10.1016/j.bjhh.2014.03.014

Ejemplares similares

Scientific comment on tumor suppressor p53 protein expression: prognostic significance in patients with low-risk myelodysplastic syndrome
por: Velloso, Elvira Deolinda Rodrigues Pereira
Publicado: (2014)

New developments in the understanding and diagnosis of myelodysplastic syndromes with ring sideroblasts()
por: Ribeiro, Lorena Bedotti, et al.
Publicado: (2016)

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
por: Sallman, David A., et al.
Publicado: (2021)

Tumor suppressor p53 protein expression: prognostic significance in patients with low-risk myelodysplastic syndrome
por: Duarte, Fernando Barroso, et al.
Publicado: (2014)

Genetic polymorphisms, chronic lymphocytic leukemia, and the future: are we there yet?
por: Caimi, Paolo F., et al.
Publicado: (2014)

Wiring the oncogenic circuitry: Pin1 unleashes mutant p53
por: Napoli, Marco, et al.
Publicado: (2011)

Hematopoietic stem cell transplantation for Hodgkin's disease
por: Patah, Poliana, et al.
Publicado: (2011)

Pseudomonas aeruginosa ventriculitis following pancytopenia due to myelodysplastic syndrome with an excess of blasts type 2
por: Scorza, Carla Alexandra, et al.
Publicado: (2023)

Triggering p53 after cytokinesis failure
por: Stukenberg, P. Todd
Publicado: (2004)

TP53 in Myelodysplastic Syndromes
por: Jiang, Yan, et al.
Publicado: (2021)

Routine Inflammatory Markers Are Elevated in Myelodysplastic Syndromes at Presentation
por: Oster, Howard S., et al.
Publicado: (2023)

Anemia and infection: a complex relationship
por: Viana, Marcos Borato
Publicado: (2011)

The invisibility of sickle cell disease in Brazil: lessons from a study in Maranhão()
por: Viana, Marcos Borato
Publicado: (2015)

TP53-mutant myelodysplastic syndrome and acute myeloid leukemia: the black hole of hematology
por: Patel, Shyam A., et al.
Publicado: (2022)

Quality of life in sickle cell disease: assessments by the 36-item Short Form Health Survey Questionnaire and Beck Depression Inventory
por: Ivo, Maria Lucia, et al.
Publicado: (2012)

Oxidative stress in sickle cell disease
por: Queiroz, Raphael Ferreira, et al.
Publicado: (2013)

‘Leaky gut’ in hematological malignancies()
por: Costa-Lima, Carolina, et al.
Publicado: (2014)

Relating protein crystal structure to ligand-binding thermodynamics
por: Helliwell, John R.
Publicado: (2022)

p53 activation: a checkpoint for precision genome editing?
por: Conti, Anastasia, et al.
Publicado: (2018)

Diarrhea after autologous stem cell transplantation in low-middle income countries: is Clostridium difficile the most prevalent infectious etiology?()
por: Cunha, Renato
Publicado: (2018)

Risk behavior disclosure among blood donors in Sao Paulo, Brazil
por: Gonçalez, Thelma Therezinha
Publicado: (2012)

A new default restraint library for the protein backbone in Phenix: a conformation-dependent geometry goes mainstream
por: Moriarty, Nigel W., et al.
Publicado: (2016)

ABO isohemagglutinin titration or hemolysin test: what should we do to reduce the risk of passive hemolysis?()
por: Castilho, Lilian
Publicado: (2015)

The p53/MDM2/MDMX-targeted therapies—a clinical synopsis
por: Jiang, Liren, et al.
Publicado: (2020)

Comment on: Consolidation treatment for high risk solid tumors in children with myeloablative chemotherapy and autologous hematopoietic progenitor stem cell transplantation
por: Kletzel, Morris
Publicado: (2013)

Myelodysplastic syndrome with progressive multifocal predominantly pontine demyelination
por: Bhattacharyya, Shamik, et al.
Publicado: (2015)

Expert consensus on the clinical application of recombinant adenovirus human p53 for head and neck cancers
por: Li, Yi, et al.
Publicado: (2021)

Comment on: Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment compliance
por: Simpson, David C
Publicado: (2013)

Telomere Attrition and p53 Response 1 (TAPR1): a new player in cancer biology?
por: dos Santos, Gabriel Arantes, et al.
Publicado: (2021)

On the need for an international effort to capture, share and use crystallization screening data
por: Newman, Janet, et al.
Publicado: (2012)

Comment on Billant et al. p53, A Victim of the Prion Fashion. Cancers 2021, 13, 269
por: Liebman, Susan W., et al.
Publicado: (2023)

Presence of new mutations in the TP53 gene in patients with low-risk myelodysplastic syndrome: two case reports
por: Duarte, Fernando Barroso, et al.
Publicado: (2017)

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
por: McGraw, K L, et al.
Publicado: (2015)

Lymphocytic Infiltrate and p53 Protein Expression as Predictive Markers of Response and Outcome in Myelodysplastic Syndromes Treated with Azacitidine
por: Pescia, Carlo, et al.
Publicado: (2021)

Regulation of Mutant p53 Protein Expression
por: Vijayakumaran, Reshma, et al.
Publicado: (2015)

Reticulocyte parameters: why should clinical laboratories evaluate and report them?
por: Proto-Siqueira, Rodrigo
Publicado: (2014)

Prophylaxis with levofloxacin: bacterial infections and antimicrobial resistance in hematological malignancies
por: Campos, Claudio Penido
Publicado: (2014)

Oral features of graft-versus-host disease
por: Regina Torres, Sandra
Publicado: (2014)

Comment: seroprevalence of HTLV-1/2 among blood donors in the state of Maranhão Brazil
por: Carvalho, Edgar M.
Publicado: (2014)

Spirituality, religiousness and health: implications for the field of hematology
por: Lucchetti, Giancarlo
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_cf1pru3cnarf4n2u8usmcb5ve6